Professor | Jinsai Shang | Asia Growth Partners

	Upload Avatar (500 x 500)
Name	Jinsai Shang
Contact Information	shang_jinsai@gzlab.ac.cn
Language ability	Chinese, English
Province	Guangdong

Upload Avatar (500 x 500)

Name

Jinsai Shang

Contact Information

shang_jinsai@gzlab.ac.cn

Language ability

Chinese, English

Province

Guangdong

University/Lab Affiliation and Title	Guangzhou Medical University
Faculty	Basic Medical Sciences
Academic Background & Achievements	2006 - Bachelor's degree in Chemistry: Wuhan University 2015 - Ph.D. in Biochemistry: Southern Illinois University Selected for High-Level Young Talent Program
Work Experience	2015-2020 - Postdoctoral Research: The Scripps Research Institute Current - Researcher: Guangzhou Laboratory / Guangzhou Medical University
Awards	2022: Selected for High-Level Young Talent Program

University/Lab Affiliation and Title

Guangzhou Medical University

Faculty

Basic Medical Sciences

Academic Background & Achievements

2006 - Bachelor's degree in Chemistry: Wuhan University
2015 - Ph.D. in Biochemistry: Southern Illinois University
Selected for High-Level Young Talent Program

Work Experience

2015-2020 - Postdoctoral Research: The Scripps Research Institute
Current - Researcher: Guangzhou Laboratory / Guangzhou Medical University

Awards

2022: Selected for High-Level Young Talent Program

Areas of Focus	Development and mechanism of action of new small molecule drugs targeting antiviral and antitumor Structure and function of drug target hormone nuclear receptors (NRs) and G protein-coupled receptors (GPCRs) Exploration of active compounds and high-throughput drug screening (HTS) based on antiviral and tumor drug targets
Publications	Structural Mechanism Underlying Ligand Binding and Activation of PPARγ, Shang J, Kojetin DJ, 2021 CAR directs T cell adaptation to bile acids in the small intestine, Chen ML, Huang X, Wang H, Hegner C, Liu Y, Shang J, Eliason A, et al, Moore DD, Sundrud MS, 2021 Structural basis for heme-dependent NCoR binding to the transcriptional repressor REV-ERBβ, Mosure SA, Strutzenberg TS, Shang J, Munoz-Tello P, Solt LA, Griffin PR, Kojetin DJ, 2021 A Molecular Switch Regulating Transcriptional Repression and Activation of PPARγ, Shang J, Mosure SA, Zheng J, Brust R, Bass J, Nichols A, Solt LA, Griffin PR and Kojetin DJ, 2020 Quantitative Structural Assessment of Graded Receptor Agonism, Shang J, Brust R, Griffin PR, Kamenecka TM and Kojetin DJ, 2019 Structural basis of altered potency and efficacy displayed by a major in vivo metabolite of the anti-diabetic PPARγ drug pioglitazone, Mosure S, Shang J, Eberhardt J, Brust R, Zheng J, Griffin PR, Forli S and Kojetin DJ, 2019 Defining a canonical ligand-binding pocket in the orphan nuclear receptor Nurr1, de Vera IM, Munoz-Tello P, Zheng J, Dharmarajan V, Marciano DP, Matta-Camacho E, Giri PK, Shang J, et al., Kojetin DJ, 2019 Cooperative Cobinding of Synthetic and Natural Ligands to the Nuclear Receptor PPARγ, Shang J, Brust R, Mosure SA, Bass J, Munoz-Tello P, Lin H, Hughes TS, Tang M, Ge Q, Kamenekca TM and Kojetin DJ, 2018 A structural mechanism for directing corepressor-selective inverse agonism of PPARγ, Brust R, Shang J, Fuhrmann J, Mosure SA, Bass J, et al., Hughes TS and Kojetin DJ, 2018 Defining a conformational ensemble that directs activation of PPARγ, Chrisman IM, Nemetchek MD#, De Vera IM#, Shang J#, Heidari Z, et al., Kojetin DJ and Hughes TS, 2018 REV-ERBα Regulates TH17 Cell Development and Autoimmunity, Amir M, Chaudhari S, Wang R, Campbell S, Mosure SA, Chopp LB, Lu Q, Shang J, et al., Kojetin DJ, Kamenecka TM and Solt LA, 2018 Chemical crosslinking mass spectrometry reveals the conformational landscape of the activation helix of PPARγ; a model for ligand-dependent antagonism, Zheng J, Corzo C, Chang MR, Shang J, Lam VQ, et al., Kojetin DJ and Griffin PR, 2018 Synergistic Regulation of Coregulator/Nuclear Receptor Interaction by Ligand and DNA, de Vera IMS, Zheng J, Novick S, Shang J, Hughes TS, et al., Griffin PR and Kojetin DJ, 2017 Probing the complex binding modes of the PPARγ partial agonist (T2384) to orthosteric and allosteric sites with NMR spectroscopy, Hughes TS#, Shang J#, Brust R, de Vera IMS, Fuhrmann J, Ruiz C, Cameron MD, Kamenecka TM and Kojetin DJ, 2016 Identification of a binding site for unsaturated fatty acids in the orphan nuclear receptor Nurr1, de Vera IM, Giri PK, Munoz-Tello P, Brust R, Fuhrmann J, Matta-Camacho E, Shang J, et al., Solt LA and Kojetin DJ, 2016 The FP domains of PI31 and Fbxo7 have the same protein fold but very different modes of protein-protein interaction, Shang J, Huang X and Du Z, 2015 Structure of the FP domain of Fbxo7 reveals a novel mode of protein–protein interaction, Shang J, Wang G, Yang Y, Huang X and Du Z, 2014 Expression, purification and crystallization of the FP domain of the human F-box protein Fbxo7, Shang J, Wang G, Yang Y, Huang X and Du Z, 2013 Fe-catalysed oxidative C–H functionalization /C–S bond formation, Wang H, Wang L, Shang J, Li X, Wang H, Gui J, Lei A, 2012

Areas of Focus

Development and mechanism of action of new small molecule drugs targeting antiviral and antitumor
Structure and function of drug target hormone nuclear receptors (NRs) and G protein-coupled receptors (GPCRs)
Exploration of active compounds and high-throughput drug screening (HTS) based on antiviral and tumor drug targets

Publications

Structural Mechanism Underlying Ligand Binding and Activation of PPARγ, Shang J, Kojetin DJ, 2021
CAR directs T cell adaptation to bile acids in the small intestine, Chen ML, Huang X, Wang H, Hegner C, Liu Y, Shang J, Eliason A, et al, Moore DD, Sundrud MS, 2021
Structural basis for heme-dependent NCoR binding to the transcriptional repressor REV-ERBβ, Mosure SA, Strutzenberg TS, Shang J, Munoz-Tello P, Solt LA, Griffin PR, Kojetin DJ, 2021
A Molecular Switch Regulating Transcriptional Repression and Activation of PPARγ, Shang J, Mosure SA, Zheng J, Brust R, Bass J, Nichols A, Solt LA, Griffin PR and Kojetin DJ, 2020
Quantitative Structural Assessment of Graded Receptor Agonism, Shang J, Brust R, Griffin PR, Kamenecka TM and Kojetin DJ, 2019
Structural basis of altered potency and efficacy displayed by a major in vivo metabolite of the anti-diabetic PPARγ drug pioglitazone, Mosure S, Shang J, Eberhardt J, Brust R, Zheng J, Griffin PR, Forli S and Kojetin DJ, 2019
Defining a canonical ligand-binding pocket in the orphan nuclear receptor Nurr1, de Vera IM, Munoz-Tello P, Zheng J, Dharmarajan V, Marciano DP, Matta-Camacho E, Giri PK, Shang J, et al., Kojetin DJ, 2019
Cooperative Cobinding of Synthetic and Natural Ligands to the Nuclear Receptor PPARγ, Shang J, Brust R, Mosure SA, Bass J, Munoz-Tello P, Lin H, Hughes TS, Tang M, Ge Q, Kamenekca TM and Kojetin DJ, 2018
A structural mechanism for directing corepressor-selective inverse agonism of PPARγ, Brust R, Shang J, Fuhrmann J, Mosure SA, Bass J, et al., Hughes TS and Kojetin DJ, 2018
Defining a conformational ensemble that directs activation of PPARγ, Chrisman IM, Nemetchek MD#, De Vera IM#, Shang J#, Heidari Z, et al., Kojetin DJ and Hughes TS, 2018
REV-ERBα Regulates TH17 Cell Development and Autoimmunity, Amir M, Chaudhari S, Wang R, Campbell S, Mosure SA, Chopp LB, Lu Q, Shang J, et al., Kojetin DJ, Kamenecka TM and Solt LA, 2018
Chemical crosslinking mass spectrometry reveals the conformational landscape of the activation helix of PPARγ; a model for ligand-dependent antagonism, Zheng J, Corzo C, Chang MR, Shang J, Lam VQ, et al., Kojetin DJ and Griffin PR, 2018
Synergistic Regulation of Coregulator/Nuclear Receptor Interaction by Ligand and DNA, de Vera IMS, Zheng J, Novick S, Shang J, Hughes TS, et al., Griffin PR and Kojetin DJ, 2017
Probing the complex binding modes of the PPARγ partial agonist (T2384) to orthosteric and allosteric sites with NMR spectroscopy, Hughes TS#, Shang J#, Brust R, de Vera IMS, Fuhrmann J, Ruiz C, Cameron MD, Kamenecka TM and Kojetin DJ, 2016
Identification of a binding site for unsaturated fatty acids in the orphan nuclear receptor Nurr1, de Vera IM, Giri PK, Munoz-Tello P, Brust R, Fuhrmann J, Matta-Camacho E, Shang J, et al., Solt LA and Kojetin DJ, 2016
The FP domains of PI31 and Fbxo7 have the same protein fold but very different modes of protein-protein interaction, Shang J, Huang X and Du Z, 2015
Structure of the FP domain of Fbxo7 reveals a novel mode of protein–protein interaction, Shang J, Wang G, Yang Y, Huang X and Du Z, 2014
Expression, purification and crystallization of the FP domain of the human F-box protein Fbxo7, Shang J, Wang G, Yang Y, Huang X and Du Z, 2013
Fe-catalysed oxidative C–H functionalization /C–S bond formation, Wang H, Wang L, Shang J, Li X, Wang H, Gui J, Lei A, 2012

Antiviral Antitumor Small Molecules Drug Development Mechanism Of Action Nuclear Receptors Gpcrs Active Compounds High-Throughput Screening Drug Targets

Dan Lu - Peking University

Jinsai Shang - Guangzhou Medical University

Yihong Peng - Peking University

View All

Personal Information

Academic Information

Research

Contact us

No account yet?

Personal Information

Academic Information

Research

Contact us